Mauna Kea Technologies
The Princess Grace Hospital Centre Chooses French Imaging System to Improve Cancer Detection Techniques and Speed Treatment

Mauna Kea Technologies / 

08.10.2009 

Dissemination of a Corporate News, transmitted by
DGAP - a company of EquityStory AG.
The issuer / publisher is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

PARIS, Oct. 8, 2009 (GLOBE NEWSWIRE) -- The Princess Grace Hospital Centre inMonaco has installed the world's smallest and most flexible imaging systemcapable of observing living, internal tissues at a microscopic level. Thetechnology, known as Cellvizio, helps physicians accurately pinpoint diseasedtissue inside the body in real time and remove it on the spot or determine aproper treatment. The GEMLUC (Groupement des Entreprises Monegasques dans la Lutte contre lecancer) group of companies in the Monaco region provided a grant for thesystem, as part of the organization's commitment to fight cancer. Developed in Paris, France, by Mauna Kea Technologies, the Cellvizio system isused with regular endoscopic tools during colonoscopies, upper endoscopies anddiagnostic procedures within the bile or pancreatic ducts to detect cancer ordisease more effectively and efficiently. Clinical trials focusing on thebiliary duct, for example, have proven that Cellvizio increases the detectionrate of unknown cancers by as much as 50%. 'We are very proud that The Princess Grace Hospital Centre has chosen Cellvizioto provide physicians with a unique in vivo imaging tool that improvesdiagnostic performance while reducing the need for additional procedures andthe long waits for biopsy results,' said Sacha Loiseau, President, CEO andFounder of Mauna Kea Technologies, speaking after the inauguration ceremonyattended by Her Royal Highness the Princess Caroline of Hanover. 'Thistechnology has been a major priority for hospitals as they realize the tangiblebenefits of early disease and cancer detection.' Physicians and thought leaders at almost one hundred top medical institutionsaround the world have completed over 3,000 procedures with Cellvizio and havepublished more than 25 peer-reviewed papers on the technology in major medicaljournals. Cellvizio has 510(k) clearance from the U.S. Food and DrugAdministration and the European CE-Mark for use in the gastrointestinal andpulmonary tracts. About Mauna Kea TechnologiesMauna Kea Technologies is a medical device company based in Paris, France. Withits flagship Cellvizio system, the company leads the growing in vivo cellularimaging market, enabling physicians to visualize, diagnose and treatpathologies that cannot be seen using other imaging techniques. Investorsinclude Psilos Group, Seventure and Creadev. For more information about MaunaKea Technologies visit www.maunakeatech.com. CONTACT: Mauna Kea Technologies         Media Contact:         Ken Purcell         +331 7008 0976         ken@maunakeatech.com
News Source: NASDAQ OMX



08.10.2009  Financial News transmitted by DGAP

---------------------------------------------------------------------------
 
Language:     English
Company:      Mauna Kea Technologies
              
               
              United States
Phone:        
Fax:          
E-mail:       
Internet:     
ISIN:         US9901025844
WKN:          
 
End of News                                     DGAP News-Service
 
---------------------------------------------------------------------------